DOCSLIB.ORG

A Meeting Report from the 6Th Isirv Antiviral Group Conference T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Meeting Report from the 6Th Isirv Antiviral Group Conference T Antiviral Research 167 (2019) 45–67 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference T ∗ John H. Beigela, , Hannah H. Namb, Peter L. Adamsc, Amy Kraffta, William L. Inced, Samer S. El-Kamaryd, Amy C. Simse a National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA bNorthwestern University, Feinberg School of Medicine, Chicago, IL, USA c Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (HHS), Washington, DC, USA d Division of Antiviral Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S Food and Drug Administration, Silver Spring, MD, USA e Gillings School of Global Public Health, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA ARTICLE INFO ABSTRACT Keywords: The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv- Influenza AVG) conference in Rockville, Maryland, November 13–15, 2018. The three-day program was focused on Respiratory syncytial virus therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including Coronavirus MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several Antiviral therapy influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, Host-directed therapeutics pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies in- cluding nitazoxanide, eritoran, and diltiazem. Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development. The aim of this report is to provide a summary of the presentations given at this meeting. 1. Background promoting the prevention, detection, treatment, and control of influ- enza and other respiratory virus diseases. The Antiviral Group is a Influenza and other acute respiratory viral diseases are of major special interest group of isirv (isirv-AVG) with specific objectives to global public health importance. Lower respiratory tract infections have promote the understanding and development of antivirals against re- been estimated to cause over 4 million deaths a year (range 3.6–4.4 spiratory viruses, and to collate and provide up to date information on million), of which approximately 40% are caused by respiratory viruses the emergence of antiviral resistance to the established therapeutics. It (Global Burden of Disease Collaborators, 2018). The emergence of high also aims to provide information on the evaluation of resistance to new morbidity viruses such as severe acute respiratory syndrome cor- therapies under development. To communicate advances in preclinical onavirus (SARS-CoV) in 2004, influenza A(H5N1) in 2005, Middle East and clinical development of potent novel antivirals five previous con- respiratory syndrome corona virus (MERS-CoV) in 2012, and influenza ferences have been organized by the isirv-AVG. A(H7N9) in 2013, as well as discovery of novel viral pathogens such as The isirv-AVG held its 6th Conference in Rockville, MD, from 13–15 human metapneumovirus in 2001 and human bocavirus in 2005 have November 2018. The three-day program was focused on therapeutics highlighted the importance of international collaboration on re- towards influenza, respiratory syncytial virus, (RSV) and other re- spiratory virus research for their prevention and control. The Interna- spiratory viruses. Topics included ongoing and recently completed tional Society for Influenza and other Respiratory Viruses Diseases clinical trials, new pre-clinical developments in therapeutics and vac- (isirv) is an independent international scientific professional society cines, regulatory considerations, and study design issues. The aim of ∗ Corresponding author. National Institute of Allergy and Infectious Diseases (NIAID), 5601 Fishers Lane, Room 7E60, MSC 9826, Rockville, MD, 20892-9826, USA. E-mail address: [email protected] (J.H. Beigel). https://doi.org/10.1016/j.antiviral.2019.04.006 Received 29 March 2019; Accepted 6 April 2019 Available online 08 April 2019 0166-3542/ Published by Elsevier B.V. J.H. Beigel, et al. Antiviral Research 167 (2019) 45–67 this conference report is to summarize the presentations given at this gram-negative bacteria endotoxin, lipopolysaccharide (LPS). TLR4 has meeting. been implicated in the pathology associated with other infections as well as tissue damage caused by non-infectious insults. The TLR4 sig- 2. Opening lecture - perspectives on advancing respiratory virus naling pathway is activated by LPS binding initially to CD14, which therapeutics transfers the LPS to a non-covalently associated TLR4 co-receptor, MD2. LPS binding to MD2 leads to TLR4 dimerization and activation. The Robert Johnson, BARDA, Washington, DC, USA. Vogel laboratory previously showed that TLR4-null mice were highly The Biomedical Advanced Research and Development Authority resistant to infection by the mouse-adapted influenza A/PR/8/ (BARDA) partners and invests in a diverse portfolio of researchers and 34(H1N1) [PR8] strain (Shirey et al., 2013), providing the rationale companies, fostering innovation and bolstering America's preparedness that blocking TLR4 signaling might be protective against influenza in- against bioterrorism threats. These partnerships have resulted in 42 fection. Eritoran, a structural analog of LPS, functions as a TLR4 an- U.S. Food & Drug Administration (FDA) approvals, licenses or clear- tagonist by binding to MD2, thereby preventing the interaction of LPS ances for 38 unique products. BARDA plans to advance respiratory virus with MD2. Eritoran was demonstrated to have therapeutic benefit in the therapeutics by focusing on three topics: improving diagnostic testing, context of protection against acute lung injury in experimental murine pursuing host-directed therapeutics, and improving the identification and cotton rat models of influenza infection. Administration of eritoran and treatment of sepsis. once daily for 5 consecutive days to wild-type mice starting 2 days after For any outbreak, the faster the identification, the faster and more PR8 infection resulted in highly significant protection against lethality robust the response. BARDA is supporting work to improve diagnostics and improved lung pathology. Moreover, a significant degree of sur- with the goal of recognizing illness before any symptoms develop. This vival was observed even when eritoran was administered to PR8-in- may include wearable diagnostics or biosensors. The high mortality fected mice starting as late as day 6 post-infection. Protection against associated with human infections with novel coronaviruses MERS-CoV influenza infection was confirmed using other TLR4 antagonists in- and SARS-CoV and avian influenza strains (influenza A(H5N1) and cluding an anti-TLR4-specific antibody, TLR4 cell-permeable decoy A(H7N9)) have raised questions about the possible role of a dysregu- peptides, a structural analog antagonist (FP7), and the small molecule lated immune response, a so called “cytokine storm”, in the patho- TLR4 antagonist, TAK242 (Perrin-Cocon et al., 2017; Piao et al., 2015). genesis of severe respiratory disease. As some patients may not respond Eritoran was also protective in cotton rats (Sigmodon hispidus) infected to typical anti-pathogen therapeutics (e.g. antivirals), BARDA is pur- with non-adapted human influenza A and B strains. suing therapeutics which target the host in order to modify the im- Since influenza is not known to express any TLR4 PAMPs, it was mune/host response. More work needs to be done to identify these host hypothesized that TLR4-activating damage-associated molecular pat- targets and develop therapeutics towards the dysregulated immune terns (DAMPs) were elicited during infection (Patel et al., 2018). In- response. The field also needs better diagnostics to guide treatment as fection of mice or cotton rats with influenza causes the release of over-suppression of the immune response can be just as dangerous as HMGB1, a host-derived protein that has been shown to be a TLR4 over-stimulation. agonist and is released from dying cells. The administration of eritoran Sepsis is one of the most urgent and costly systemic health threats blocks release of HMGB1 and blunts influenza-induced cytokine in- and is a common pathway for mortality associated with novel patho- duction which, in turn, results in improved lung function, reversal of gens. The current approach is to develop better diagnostics to identify edema, and reduced viral titer. Moreover, administration of an HMGB1 and treat sepsis early, and understand the immune profile (activation small molecule antagonist provides the same degree of protection to versus suppression) in this disease. BARDA's Division of Research, PR8-infected mice as eritoran. Innovation, and Ventures (DRIVe) is establishing unique public-private The development
Load more

Recommended publications
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Microorganisms-07-00521-V2.Pdf
    microorganisms Review Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients? Cristian-Marian Popescu 1,* , Aurora Livia Ursache 2, Gavriela Feketea 1 , Corina Bocsan 3, Laura Jimbu 1, Oana Mesaros 1, Michael Edwards 4,5, Hongwei Wang 6, Iulia Berceanu 7, Alexandra Neaga 1 and Mihnea Zdrenghea 1,7,* 1 Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Babes str., 400012 Cluj-Napoca, Romania; [email protected] (G.F.); [email protected] (L.J.); [email protected] (O.M.); [email protected] (A.N.) 2 The Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Calea Mănăs, tur 3-5, 400372 Cluj-Napoca, Romania; [email protected] 3 Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Ha¸tieganuUniversity of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania; [email protected] 4 National Heart and Lung Institute, St Mary’s Campus, Imperial College London, London W2 1PG, UK; [email protected] 5 Medical Research Council (MRC) and Asthma UK Centre in Allergic Mechanisms of Asthma, London W2 1PG, UK 6 School of Medicine, Nanjing University, 22 Hankou Road, Nanjing 210093, China; [email protected] 7 Department of Hematology, Ion Chiricuta Oncology Institute, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania; [email protected] * Correspondence: [email protected] (C.-M.P.); [email protected] (M.Z.) Received: 8 October 2019; Accepted: 31 October 2019; Published: 2 November 2019 Abstract: Despite a plethora of studies demonstrating significant morbidity and mortality due to community-acquired respiratory viral (CRV) infections in intensively treated hematology patients, and despite the availability of evidence-based guidelines for the diagnosis and management of respiratory viral infections in this setting, there is no uniform inclusion of respiratory viral infection management in the clinical hematology routine.
    [Show full text]
  • Drug Repurposing for Identification of Potential Inhibitors Against SARS-Cov-2 Spike Receptor-Binding Domain: an in Silico Approach
    Indian J Med Res 153, January & February 2021, pp 132-143 Quick Response Code: DOI: 10.4103/ijmr.IJMR_1132_20 Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach Santosh Kumar Behera1, Namita Mahapatra1, Chandra Sekhar Tripathy1 & Sanghamitra Pati2 1Health Informatics Centre, 2ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India Received April 10, 2020 Background & objectives: The world is currently under the threat of coronavirus disease 2019 (COVID-19) infection, caused by SARS-CoV-2. The objective of the present investigation was to repurpose the drugs with potential antiviral activity against receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein among 56 commercially available drugs. Therefore, an integrative computational approach, using molecular docking, quantum chemical calculation and molecular dynamics, was performed to unzip the effective drug-target interactions between RBD and 56 commercially available drugs. Methods: The present in silico approach was based on information of drugs and experimentally derived crystal structure of RBD of SARS-CoV-2 S protein. Molecular docking analysis was performed for RBD against all 56 reported drugs using AutoDock 4.2 tool to screen the drugs with better potential antiviral activity which were further analysed by other computational tools for repurposing potential drug or drugs for COVID-19 therapeutics. Results: Drugs such as chalcone, grazoprevir, enzaplatovir, dolutegravir, daclatasvir, tideglusib, presatovir, remdesivir and simeprevir were predicted to be potentially effective antiviral drugs against RBD and could have good COVID-19 therapeutic efficacy. Simeprevir displayed the highest binding affinity and reactivity against RBD with the values of −8.52 kcal/mol (binding energy) and 9.254 kcal/mol (band energy gap) among all the 56 drugs under investigation.
    [Show full text]
  • Development of Novel Anti-Respiratory Syncytial Virus Therapies
    Development of Novel Anti-Respiratory Syncytial Virus Therapies by Michael J Norris A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Laboratory Medicine and Pathobiology University of Toronto © Copyright by Michael J Norris 2017 Development of Novel Anti-Respiratory Syncytial Virus Therapies Michael J Norris Doctor of Philosophy Laboratory Medicine and Pathobiology University of Toronto 2017 Abstract Respiratory syncytial virus (RSV) is a leading cause of mortality in infants and young children. Despite the RSV disease burden, no vaccine is available and treatment remains non-specific. New drug candidates are needed to combat RSV. Towards this goal, we investigated two broad strategies to control RSV infection. First, we examined the utility of delivering an anti-4-1BB agonist antibody to enhance CD8 T cell costimulation in a mouse model of RSV infection. This strategy enhanced CD8 T cell numbers, however failed to reduce RSV titers in the lung. We found that this was likely due to reduced RSV specific CD8 T cells in the lung. Overall, this strategy did not attenuate RSV associated disease outcomes and was associated with increased morbidity. Second, we screened over 2000 FDA approved compounds to identify approved drugs with novel anti-RSV activity. Cardiac glycosides, inhibitors of the membrane bound Na+/K+-ATPase, were identified to have anti-RSV activity. Cardiac glycosides diminished RSV infection in HEp-2 cells and in primary human airway epithelial cells grown at an air liquid interface. Digoxin, an FDA approved cardiac glycoside, was further able to inhibit RSV infection of community isolates of RSV in primary nasal epithelial cells.
    [Show full text]
  • Current and Novel Approaches in Influenza Management
    Review Current and Novel Approaches in Influenza Management Erasmus Kotey 1,2,3 , Deimante Lukosaityte 4,5, Osbourne Quaye 1,2 , William Ampofo 3 , Gordon Awandare 1,2 and Munir Iqbal 4,* 1 West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Legon, Accra P.O. Box LG 54, Ghana; [email protected] (E.K.); [email protected] (O.Q.); [email protected] (G.A.) 2 Department of Biochemistry, Cell & Molecular Biology, University of Ghana, Legon, Accra P.O. Box LG 54, Ghana 3 Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana; [email protected] 4 The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey GU24 0NF, UK; [email protected] 5 The University of Edinburgh, Edinburgh, Scotland EH25 9RG, UK * Correspondence: [email protected] Received: 20 May 2019; Accepted: 17 June 2019; Published: 18 June 2019 Abstract: Influenza is a disease that poses a significant health burden worldwide. Vaccination is the best way to prevent influenza virus infections. However, conventional vaccines are only effective for a short period of time due to the propensity of influenza viruses to undergo antigenic drift and antigenic shift. The efficacy of these vaccines is uncertain from year-to-year due to potential mismatch between the circulating viruses and vaccine strains, and mutations arising due to egg adaptation. Subsequently, the inability to store these vaccines long-term and vaccine shortages are challenges that need to be overcome. Conventional vaccines also have variable efficacies for certain populations, including the young, old, and immunocompromised.
    [Show full text]
  • Communication DOI: 10.5582/Ddt.2020.01012
    58 Drug Discoveries & Therapeutics. 2020; 14(1):58-60. Communication DOI: 10.5582/ddt.2020.01012 Discovering drugs to treat coronavirus disease 2019 (COVID-19) Liying Dong1, Shasha Hu2, Jianjun Gao1,* 1 Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China; 2 Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. SUMMARY The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2. Keywords novel coronavirus, pneumonia, COVID-19, 2019-nCoV, SARS-CoV-2 The virus SARS-CoV-2 (formerly designated 2019- day. Ribavirin should be administered via intravenous nCoV) emerged in December 2019 and then spread infusion at a dose of 500 mg for adults, 2 to 3 times/ rapidly worldwide, particularly to China, Japan, and day in combination with IFN-α or lopinavir/ritonavir. South Korea. As of February 21, 2020, a total of Chloroquine phosphate is orally administered at a dose 76,288 confirmed cases of coronavirus disease 2019 of 500 mg (300 mg for chloroquine) for adults, 2 times/ (COVID-19) and 2,345 deaths have been reported in day. Arbidol is orally administered at a dose of 200 mg mainland China (1).
    [Show full text]
  • 1 Combined Effect of Anti-High-Mobility Group Box-1 Monoclonal Antibody and Peramivir Against Influenza a Virus-Induced Pneumoni
    Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice Kazuki Hatayama1; Nobuyuki Nosaka1*; Mutsuko Yamada1; Masato Yashiro1; Yosuke Fujii1; Hirokazu Tsukahara1; Keyue Liu3; Masahiro Nishibori3; Akihiro Matsukawa4; Tsuneo Morishima1,2 1 Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2 Department of Pediatrics, Aichi Medical University, Japan 3 Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 4 Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 1 *Correspondence author: Nobuyuki Nosaka 2-5-1 Shikata-cho, Kita-ku, Okayama city, Okayama pref. 700-8558, Japan Tel: +81-86-235-7249 Email: [email protected] Shortened title: Anti-HMGB1 plus peramivir for influenza 2 ABSTRACT Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury (ALI) due to excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi.
    [Show full text]
  • RSV in the Elderly. Troubled Past, Dark Present, Bright Future?
    RSV infection in the elderly troubled past, dark present, bright future ? Nicolas Dauby MD, PhD, Infectious Diseases Department - CHU Saint Pierre 4th April 2019 – SBIMC-SBP-BSGG Symposium In collaboration with Valérie Martinet MD, PhD, Geriatrics, CHU Saint Pierre Outline 1. Introduction 2. Mechanisms of RSV disease in elderly 3. Epidemiology and burden 4. Future therapeutical intervention 5. Prevention : vaccination Respiratory syncytial virus (RSV) • Discovered in 1956 • Enveloped RNA virus • Common & ubiquitous respiratory virus • North hemisphere : Annual epidemics during the cold season (nov-march) • A & B subtypes Seasonality of RSV infection Alberta, Canada 2008-2015 Proportion of RSV positive assay by luminex Assay Griffiths CMR 2017 Age as a major determinant of RSV disease Most common respiratory infection in infants 95% infected before 2 years Openshaw Annual Rev Immunol 2017 1. Introduction 2. Mechanisms of RSV disease in elderly 3. Epidemiology and burden 4. Future therapeutical intervention 5. Prevention : vaccination Pathways leading to antiviral defense & immunopathology during RSV infection Protective vs Harmful immunity Openshaw, Annual Rev Immunol 2017 Impact of aging on systemic immune functions Defective phagocytosis Defective phagocytosis Reduced functions Inflammaging Lower effector functions Reduced proliferation The ageing lung Alveolar epithelial cells Pro-Inf. Cytokines Neutrophils Functionality Bowdish Chest 2019 Mechanisms of diseases in the elderly • Lower frequency of RSV-specific CD8 T cells – Associated
    [Show full text]
  • Study Protocol
    NCT03376321 Janssen Research & Development * Clinical Protocol A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection Protocol 63623872FLZ3001; Phase 3 AMENDMENT 2 JNJ-63623872-ZCD Pimodivir *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol. This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312). EudraCT NUMBER: 2017-002156-84 Status: Approved Date: 11 June 2019 Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV EDMS number: EDMS-ERI-121941709, 10.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them.
    [Show full text]
  • Improving Pipeline for the Development of Influenza Antivirals
    United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Improving Pipeline for the Development of Influenza Antivirals Michael W Wathen, Ph.D. Chief, Antiviral Advanced Development Influenza Division BARDA BARDA Influenza Antiviral Program Strategy Overview National Strategy Issues BARDA Strategy ASPR: Resilient People. Healthy Communities. A Nation Prepared. 2 Issues for Influenza Antivirals • Current therapies have narrow treatment window ─ Treatment within 48h of symptom onset for neuraminidase inhibitors ─ Can treatment window be expanded with novel antivirals having different mechanisms of action? • Constant threat of resistance ─ Value of M-2 blockers minimized by resistance ─ Heavy reliance on neuraminidase inhibitors ─ Few combination therapies unavailable • Limited options in U.S. for special populations ─ No IV formulations approved for patients on ventilators ─ No drugs approved for severely ill, hospitalized patients ─ Limited treatment options for pediatric patients ASPR: Resilient People. Healthy Communities. A Nation Prepared. 3 BARDA Influenza Antiviral Program Advanced Development Strategy 2005 National Strategy for Pandemic Influenza • Accelerate development, evaluation, approval and U.S.-based production of new influenza antiviral drugs Treatment Gap Issues • Special populations (pediatrics, severely ill hospitalized) Existing BARDA Advanced Development Projects • Fill critical unmet medical needs by expanding the utility of neuraminidase inhibitors •Peramivir •$235M contract with BioCryst awarded in 2007 •Development of IV peramivir in hospitalized patients •EUA designated by FDA during 2009 pandemic •First unapproved drug authorized for use under an EUA •Worldwide clinical program for licensure in U.S. •Laninamivir •$231M contract with Biota awarded in 2011 •Development of inhaled laninamivir in outpatient setting •Single-dose treatment course ASPR: Resilient People.
    [Show full text]
  • Hydrophobic Amino-Terminal Pocket CD14 Reveals a Bent Solenoid with a the Crystal Structure of Human Soluble
    The Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal Pocket This information is current as Stacy L. Kelley, Tiit Lukk, Satish K. Nair and Richard I. of September 25, 2021. Tapping J Immunol 2013; 190:1304-1311; Prepublished online 21 December 2012; doi: 10.4049/jimmunol.1202446 http://www.jimmunol.org/content/190/3/1304 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/12/31/jimmunol.120244 Material 6.DC1 http://www.jimmunol.org/ References This article cites 87 articles, 45 of which you can access for free at: http://www.jimmunol.org/content/190/3/1304.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal Pocket Stacy L.
    [Show full text]
  • Advancing the Development Pipeline for the Treatment of Influenza
    United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Advancing the Development Pipeline for the Treatment of Influenza Melissa Willis, Ph.D. Chief, Influenza Therapeutics Influenza Division BARDA Roadmap • What is our goal? • Where have we been? • Where are we going? • Why now? • What strategies we are pursuing to achieve the goal? ASPR: Resilient People. Healthy Communities. A Nation Prepared. 2 BARDA Influenza Antiviral Program Program Goal “Reduce morbidity and mortality in all patient populations during an influenza pandemic by supporting advanced development, evaluation, and approval of new influenza antiviral drugs” • Mission established in the 2005 National Strategy for Pandemic Influenza, HHS Pandemic Influenza Plan and the 2006 Implementation Plan for the National Strategy for Pandemic Influenza • Initial stockpiling goal and advanced development projects • Stockpile total of 81M treatment courses of influenza antiviral drugs • Advanced development of new antiviral drugs • New BARDA advanced development projects are focused on developing drugs to address critical unmet needs in treating severely ill, hospitalized patients and in pediatric populations • Novel mechanisms of action • Combination therapy Our total reliance on monotherapy with NAI’s has placed us at risk of no treatment options to ASPR:address Resilient a potentialPeople. Healthy NAI- resistantCommunities. pandemic A Nation Prepared. 3 BARDA Influenza Therapeutics Program Line-Up • Two large, full development
    [Show full text]